EUVIMEDEUVIMED entdecken
Crossref

First-in-Human Evaluation of [ 68 Ga]Ga-HTK03149, a PSMA-Targeted Tracer for PET Imaging in Prostate Cancer

Guillaume Chaussé, Xinchi Hou, Carlos Uribe, Sara Harsini, Jinhe Pan, Heather Saprunoff, Hayley Allan, Hsiou-Ting Kuo, Kuo-Shyan Lin, Don Wilson, François Bénard

Journal of Nuclear Medicine · 2026

DOI: 10.2967/jnumed.123.266357 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2026. Verfasst von Guillaume Chaussé und 10 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Imaging and Therapy, BC Cancer, Vancouver, British Columbia, Canada; and. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Glutamate Carboxypeptidase II, Antigens, Surface, Gallium Radioisotopes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate-specific membrane antigen (PSMA) is a validated target for prostate cancer imaging and therapy. [68Ga]Ga-HTK03149 is a PSMA inhibitor designed to improve biodistribution by incorporating a 2-aminoadipic acid moiety as an alternative PSMA binding group. We report the first-in-human safety, biodistribution, and dosimetry evaluation of [68Ga]Ga-HTK03149 and explore organ uptake relevant to future theranostic use.

Methods

Men with biochemical recurrence of prostate cancer (prostate-specific antigen, >0.4 ng/mL) after definitive local therapy were enrolled. Each participant underwent a 60-min dynamic PET/CT scan (heart-focused for the first 6 min and then serial whole-body passes), followed by static whole-body acquisitions at 1 and 2 h after injection. In 5 participants, intravenous furosemide (40 mg) was given after the 1-h scan. Volumes of interest were drawn manually, and organ absorbed doses were calculated using OLINDA/EXM version 2.2.

Results

Ten men (median age, 68 y; range, 61-74 y; median prostate-specific antigen, 3.3 ng/mL; range, 0.42-9.6 ng/mL) completed imaging without adverse events. Vital signs and laboratory parameters showed no clinically relevant changes. [68Ga]Ga-HTK03149 cleared rapidly from blood and soft tissue, with prominent uptake in the lacrimal and salivary glands, liver, spleen, kidneys, and small intestine, as well as urinary excretion. The kidneys received the highest absorbed dose (0.107 ± 0.020 mGy/MBq), followed by the salivary glands (0.067 ± 0.019 mGy/MBq) and lacrimal glands (0.063 ± 0.026 mGy/MBq). The mean effective dose was 0.012 ± 0.005 mSv/MBq. Forced diuresis significantly reduced the urinary bladder wall dose (0.029 ± 0.0097 vs. 0.056 ± 0.0268 mGy/MBq, P = 0.04) but did not affect the kidney dose (P = 0.99). Lesions (n = 16 in 9/10 patients) showed high uptake and improved contrast at 2 h, with an SUVmax of 7.13 (range, 5.44-10.99) at 1 h versus 9.52 (range, 7.07-13.67) at 2 h (P < 0.001) and a tumor-to-background ratio of 15.74 (range, 10.85-21.09) at 1 h versus 20.42 (range, 12.50-27.51) at 2 h (P < 0.001). Conclusion: [68Ga]Ga-HTK03149 is a safe PSMA-targeted PET radiopharmaceutical with biodistribution and radiation dosimetry comparable to those of existing tracers. Its high tumor uptake and improved delayed lesion contrast support further clinical evaluation for prostate cancer imaging and theranostic applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsGlutamate Carboxypeptidase IIAntigens, SurfaceGallium RadioisotopesPositron Emission Tomography Computed TomographyMaleHumansTissue DistributionMiddle AgedAgedRadioactive TracersRadiometry

Stichwörter der Autor:innen

PET/CTPSMA[68Ga]Ga-HTK03149dosimetryprostate cancer

Substanzen

Glutamate Carboxypeptidase IIAntigens, SurfaceGallium RadioisotopesFOLH1 protein, humanRadioactive Tracers

Autor:innen und Institutionen

  • Molecular Imaging and Therapy, BC Cancer, Vancouver, British Columbia, Canada; and.
  • Department of Radiology, University of British Columbia, Vancouver, British Columbia, Canada.
  • Molecular Imaging and Therapy, BC Cancer, Vancouver, British Columbia, Canada; and dwilson@bccancer.bc.ca.

Zitieren

APA

Chaussé, G., Hou, X., Uribe, C., Harsini, S., Pan, J., Saprunoff, H., Allan, H., Kuo, H. T., Lin, K. S., Wilson, D., & Bénard, F. (2026). First-in-Human Evaluation of [ 68 Ga]Ga-HTK03149, a PSMA-Targeted Tracer for PET Imaging in Prostate Cancer. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.123.266357

Vancouver

Chaussé G, Hou X, Uribe C, Harsini S, Pan J, Saprunoff H, et al. First-in-Human Evaluation of [ 68 Ga]Ga-HTK03149, a PSMA-Targeted Tracer for PET Imaging in Prostate Cancer. Journal of Nuclear Medicine. 2026. doi:10.2967/jnumed.123.266357

BibTeX
@article{Chauss2026,
  author = {Chaussé, Guillaume and Hou, Xinchi and Uribe, Carlos and Harsini, Sara and Pan, Jinhe and Saprunoff, Heather and Allan, Hayley and Kuo, Hsiou-Ting and Lin, Kuo-Shyan and Wilson, Don and Bénard, François},
  title = {First-in-Human Evaluation of [ 68 Ga]Ga-HTK03149, a PSMA-Targeted Tracer for PET Imaging in Prostate Cancer},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  doi = {10.2967/jnumed.123.266357}
}
Kostenlos starten →